Ficolin-2 is a lectin complement pathway activator present in normal human plasma and usually associated with infectious diseases, but little is known about the role of ficolin-2 in human immunodeficiency virus (HIV) infection. Here, we describe our novel findings that serum ficolin-2 concentrations of 103 HIV-1 patients were much higher compared to those of 57 healthy donors. In vitro analysis showed that HIV-1 infection could enhance ficolin-2 expression. We further demonstrated that recombinant ficolin-2 protein could bind with HIV-1 envelope glycoprotein gp120, and subsequently induce complement dependent cytotoxicity. Moreover, ficolin-2 could block the entry of HIV-1 into target cells (TZM-b1 and MT-2 cells) and infection in a ficolin-2 dosedependent manner. To our knowledge, this is the first report about the protective role of ficolin-2 against HIV-1 infection and our study suggests that ficolin-2 is an important human innate immune molecule against HIV.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Atkinson AP, Cedzynski M, Szemraj J, Swierzko A, Bak-Romaniszyn L, Banasik M, Zeman K, Matsushita M, Turner ML, Kilpatrick DC. 2004. L-ficolin in children with recurrent respiratory infections. Clin Exp Immunol, 138: 517–520.
Chapman SJ, Vannberg FO, Khor CC, Segal S, Moore CE, Knox K, Day NP, Davies RJ, Crook DW, Hill AV. 2007. Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. Mol Immunol, 44: 3267–3270.
Chen T, Hu Y, Ding Q, Yu J, Wang F, Luo F, Zhang XL. 2015. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases. Virol Sin, 30: 249–260.
Dimitrov DS. 2000. Cell biology of virus entry. Cell, 10: 697–702.
Endo Y, Sato Y, Matsushita M, Fujita T. 1996. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics, 36: 515–521.
Ezekowitz RAB, Kuhlman M, Groopman JE, Byrn RA. 1989. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med, 169: 185–196.
Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. 2006. Mannosebinding lectin and its genetic variants. Genes Immun, 7: 85e94.
Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, Kanki PJ. 2003. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med, 22: 573–593.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. 2009. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, 373: 48–57.
Haurum JS, Thiel S, Jones IM, Fische PB, Laursen SB, Jensenius JC. 1993. Complement activation upon binding of mannanbinding protein to HIV envelope glycoproteins. Aids, 7: 1307–1313.
Hoffmann JA, Kafatos FC, Janeway Jr. CA, Ezekowitz RAB. 1999. Phylogenetic perspectives in innate immunity. Science, 284: 1313–1318.
Hummelshøj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, Garred P. 2007. Molecular organization of human Ficolin-2. Mol Immunol, 44: 401–411.
Hu Q, Napier KB, Trent JO, Wang Z, Taylor S, Griffin GE, Peiper SC, Shattock RJ. 2005. Restricted Variable Residues in the Cterminal Segment of HIV-1 V3 Loop Regulate the Molecular Anatomy of CCR5 Utilization. J Mol Biol, 350: 699–712.
Ichijo H, Ronnstrand L, Miyagawa K, Ohashi H, Heldin CH, Miyazono K. 1991. Purification of transforming growth factorbeta 1 binding proteins from porcine uterus membranes. J Biol Chem, 266: 22459–22464.
Keeffe JR, Gnanapragasam PNP, Gillespie SK, Yong J, Bjorkman PJ, Mayo SL. 2011. Designed oligomers of cyanovirin-N show enhanced HIV neutralization. P Natl Acad Sci USA, 108: 14079–14084.
Kilpatrick DC, McLintock LA, Allan EK, Copland M, Fujita T, Jordanides NE, Koch C, Matsushita M, Shiraki H, Stewart K, Tsujimura M, Turner ML. 2003. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapyrelated infections. Clin Exp Immunol, 134: 279–284.
Lars H, Tom E M, Thor U, Bjørn C, Pål A, Stig SF. 2003. Mannose-binding lectin in HIV infection: relation to disease progression and highly active antiretroviral therapy. JAIDS, 32: 354–361.
Li GR, Liu J, Pan Q, Song ZB, Luo FL, Wang SR, Zhang XL, Zhou X. 2009. Synthesis and anti-HIV activity of [ddN]-[ddN] dimers and benzimidazole nucleoside dimers. Chem Biodivers, 6: 2200–2207.
Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol, 82: 638–651.
Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang XL. 2009. Specifically binding of Lficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol, 6: 235–244.
Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T. 2005. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol, 175: 3150–3156.
Lu J, Le Y. 1998. Ficolins and the fibrinogen-like domain. Immunobiology, 199: 190–199.
Lu J, Le Y, Kon OL, Chan J, Lee SH. 1996. Biosynthesis of human ficolin, an Escherichia coli-binding protein, by monocytes: Comparison with the synthesis of two macrophage-specific proteins, C1q and the mannose receptor. Immunology, 89: 289–294.
Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizuochi T. 1996. A novel human serum lectin with collagen-and fibrinogen-like domains that functions as an opsonin. J Biol Chem, 271: 2448–2454.
Pan Q, Chen H, Wang F, Jeza ViT, Hou W, Zhao Y, Xiang T, Zhu Y, EndoY, Fujita T, Zhang XL. 2012. L-ficolin binds to glycoproteins HA and NA and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun, 4: 312–324.
Saarloos MN, Lint TF, Spear GT. 1995. Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells. Clin Exp Immunol, 99: 189–195.
Sarma JV, Ward PA. 2011. The complement system. Cell Tissue Res, 343: 227–235.
Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N. 1998. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem, 273: 20721–20727.
Trujillo JR, Rogers R, Molina R M, Dangond F, McLane MF, Essex M, Brain JD. 2007. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc Natl Acad Sci USA, 104: 5097–5102.
Tullis RH, Duffin RP, Handley HH, Sodhi P, Menon J, Joyce JA, Kher V. 2009. Reduction of hepatitis C virus using Lectin affinity plasmapheresis in dialysis patients. Blood Purificat, 27: 64–69.
Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science, 280: 1884–1888.
Williams BG, Granich R, Dye C. 2011. Role of acute infection in HIV transmission. Lancet, 378: 1913.
Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT. 2004. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses, 20: 327–335.
Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL. 2014. Ficolin-2 inhibits Hepatitis C Virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol, 193: 783–796.
Zhang XL, Liu M, Xie P, Wan S, Yea JT, Zhou X, Wu J. 2004. Specific inhibition effects of N-pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells. Bioorg Med Chem Lett, 14: 3789–3792.
Rights and permissions
About this article
Cite this article
Luo, F., Chen, T., Liu, J. et al. Ficolin-2 binds to HIV-1 gp120 and blocks viral infection. Virol. Sin. 31, 406–414 (2016). https://doi.org/10.1007/s12250-016-3808-3